In spite of shortcomings in existing studies, and in agreement with findings in mCRC in general, PM-CRC patients with tumors that have mutations in the BRAF oncogene have been identified as a subgroup with less favorable prognosis than BRAF wild-type cases. Here, BRAF is linked to colorectal carcinoma.